Biopharmaceutical Company Announces Positive Interim Results For Non-Hodgkin's Lymphoma

Groundbreaking Phase 1 Results for CASI Pharmaceuticals’ BI-1206 Treatment for Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China.

The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of any other agency, organization, employer or company. The information provided in this article is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Alw…